Treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid analgesics. Despite the increasing availability of generic analgesics from these drug classes, as well as the continued entrenchment of select therapies as key treatment options for neuropathic pain, unmet need for novel analgesics—particularly those with novel mechanisms of action—remains, driven by the growing prevalence of the neuropathic pain patient population and the sizable percentage of patients refractory to current treatment.
- What is the current state of treatment for neuropathic pain? What are interviewed experts’ insights on current treatment options?
- What are interviewed experts’ views on late-phase emerging therapies such as Teva’s TV-45070, Grünenthal’s cebranopadol, Daiichi Sankyo’s mirogabalin, and Pfizer’s pregabalin CR as potential treatments for neuropathic pain?
- What is the commercial potential of late-phase pipeline analgesic products in the neuropathic pain market should they launch?
- How will the neuropathic pain market evolve over the next decade in light of expanding generic competition and the entrance of new treatment options through 2026?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.